Discontinuation of odanacatib and other osteoporosis treatments: Here today and gone tomorrow?

@article{Bauer2011DiscontinuationOO,
  title={Discontinuation of odanacatib and other osteoporosis treatments: Here today and gone tomorrow?},
  author={D. Bauer},
  journal={Journal of Bone and Mineral Research},
  year={2011},
  volume={26}
}
  • D. Bauer
  • Published 2011
  • Medicine
  • Journal of Bone and Mineral Research
  • The options available for effective osteoporosis treatment continue to grow. Because of the large number of treatment options, many clinicians, particularly in primary care, are uncertain about when to start therapy, which drug to use, and when to stop. The issue of when to stop antifracture therapy is now front and center as evidence accumulates that the antifracture benefits of some treatments persist after discontinuation and as patients increasingly voice concerns about possible rare but… CONTINUE READING
    19 Citations
    Clinical considerations for the use of antiresorptive agents in the treatment of metastatic bone disease.
    • P. Hadji
    • Medicine
    • Critical reviews in oncology/hematology
    • 2011
    • 15
    Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences
    • 43
    Potential role of odanacatib in the treatment of osteoporosis
    • K. W. Ng
    • Medicine
    • Clinical interventions in aging
    • 2012
    • 34
    • PDF
    Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis
    • 23
    • Highly Influenced
    • PDF
    Newer Adult Bone Drugs

    References

    SHOWING 1-10 OF 16 REFERENCES
    To stop or not to stop, that is the question
    • E. Seeman
    • Medicine
    • Osteoporosis International
    • 2008
    • 54
    Fracture risk remains reduced one year after discontinuation of risedronate
    • 182
    Safety of bisphosphonates in the treatment of osteoporosis.
    • 88
    Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three‐year continued therapy and resolution of effect
    • J. Eisman, H. Bone, +11 authors A. Lombardi
    • Medicine
    • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
    • 2011
    • 233
    • Highly Influential
    • PDF
    Odanacatib, a cathepsin‐K inhibitor for osteoporosis: A two‐year study in postmenopausal women with low bone density
    • H. Bone, M. Mcclung, +7 authors B. Ince
    • Medicine
    • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
    • 2010
    • 310
    • Highly Influential
    Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long‐Term Extension
    • K. Ensrud, E. Barrett-connor, +9 authors D. Black
    • Medicine
    • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
    • 2004
    • 247
    • PDF
    The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)
    • D. Black, I. Reid, +14 authors R. Eastell
    • Medicine
    • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
    • 2012
    • 463
    • PDF
    Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    • 328
    • PDF
    Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies
    • 143
    • Highly Influential